-
Something wrong with this record ?
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
T. Spelman, S. Ozakbas, R. Alroughani, M. Terzi, S. Hodgkinson, G. Laureys, T. Kalincik, A. Van Der Walt, B. Yamout, J. Lechner-Scott, A. Soysal, J. Kuhle, JL. Sanchez-Menoyo, Y. Blanco Morgado, D. Spitaleri, V. van Pesch, D. Horakova, R. Ampapa,...
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Dimethyl Fumarate therapeutic use MeSH
- Fingolimod Hydrochloride therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Cladribine therapeutic use MeSH
- Humans MeSH
- Recurrence MeSH
- Registries MeSH
- Multiple Sclerosis, Relapsing-Remitting * drug therapy MeSH
- Retrospective Studies MeSH
- Multiple Sclerosis * drug therapy MeSH
- Tablets therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience. OBJECTIVES: Use real-world data to compare treatment patterns and clinical outcomes in people with MS (pwMS) treated with cladribine tablets versus other oral DMTs. METHODS: Retrospective treatment comparisons were based on data from the international MSBase registry. Eligible pwMS started treatment with cladribine, fingolimod, dimethyl fumarate, or teriflunomide tablets from 2018 to mid-2021 and were censored at treatment discontinuation/switch, death, loss to follow-up, pregnancy, or study period end. Treatment persistence was evaluated as time to discontinuation/switch; relapse outcomes included time to first relapse and annualized relapse rate (ARR). RESULTS: Cohorts included 633 pwMS receiving cladribine tablets, 1195 receiving fingolimod, 912 receiving dimethyl fumarate, and 735 receiving teriflunomide. Individuals treated with fingolimod, dimethyl fumarate, or teriflunomide switched treatment significantly more quickly than matched cladribine tablet cohorts (adjusted hazard ratio (95% confidence interval): 4.00 (2.54-6.32), 7.04 (4.16-11.93), and 6.52 (3.79-11.22), respectively). Cladribine tablet cohorts had significantly longer time-to-treatment discontinuation, time to first relapse, and lower ARR, compared with other oral DMT cohorts. CONCLUSION: Cladribine tablets were associated with a significantly greater real-world treatment persistence and more favorable relapse outcomes than all oral DMT comparators.
Al Amiri Hospital Kuwait City Kuwait
Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino Avellino Ital
Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases Istanbul Turkey
Center of Neuroimmunology Service of Neurology Hospital Clinic de Barcelona Barcelona Spain
Cliniques Universitaires Saint Luc Brussels Belgium
Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia Catania Italy
Department of Neurology 19 Mayis University Samsun Turkey
Department of Neurology Austin Health Melbourne VIC Australia
Department of Neuroscience Central Clinical School Monash University Melbourne VIC Australia
Division of Neurology St Michael's Hospital University of Toronto Toronto ON Canada
Dokuz Eylul University Izmir Turkey
EMD Serono Research and Development Institute Inc Billerica MA USA an affiliate of Merck KGaA
Liverpool Hospital Sydney NSW Australia
MSBase Foundation Melbourne VIC Australia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004381
- 003
- CZ-PrNML
- 005
- 20230425141334.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/13524585221137502 $2 doi
- 035 __
- $a (PubMed)36433775
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spelman, Tim $u MSBase Foundation, Melbourne, VIC, Australia $1 https://orcid.org/0000000192043216
- 245 10
- $a Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry / $c T. Spelman, S. Ozakbas, R. Alroughani, M. Terzi, S. Hodgkinson, G. Laureys, T. Kalincik, A. Van Der Walt, B. Yamout, J. Lechner-Scott, A. Soysal, J. Kuhle, JL. Sanchez-Menoyo, Y. Blanco Morgado, D. Spitaleri, V. van Pesch, D. Horakova, R. Ampapa, F. Patti, R. Macdonell, A. Al-Asmi, O. Gerlach, J. Oh, A. Altintas, N. Tundia, SL. Wong, H. Butzkueven
- 520 9_
- $a BACKGROUND: Effectiveness of cladribine tablets, an oral disease-modifying treatment (DMT) for multiple sclerosis (MS), was established in clinical trials and confirmed with real-world experience. OBJECTIVES: Use real-world data to compare treatment patterns and clinical outcomes in people with MS (pwMS) treated with cladribine tablets versus other oral DMTs. METHODS: Retrospective treatment comparisons were based on data from the international MSBase registry. Eligible pwMS started treatment with cladribine, fingolimod, dimethyl fumarate, or teriflunomide tablets from 2018 to mid-2021 and were censored at treatment discontinuation/switch, death, loss to follow-up, pregnancy, or study period end. Treatment persistence was evaluated as time to discontinuation/switch; relapse outcomes included time to first relapse and annualized relapse rate (ARR). RESULTS: Cohorts included 633 pwMS receiving cladribine tablets, 1195 receiving fingolimod, 912 receiving dimethyl fumarate, and 735 receiving teriflunomide. Individuals treated with fingolimod, dimethyl fumarate, or teriflunomide switched treatment significantly more quickly than matched cladribine tablet cohorts (adjusted hazard ratio (95% confidence interval): 4.00 (2.54-6.32), 7.04 (4.16-11.93), and 6.52 (3.79-11.22), respectively). Cladribine tablet cohorts had significantly longer time-to-treatment discontinuation, time to first relapse, and lower ARR, compared with other oral DMT cohorts. CONCLUSION: Cladribine tablets were associated with a significantly greater real-world treatment persistence and more favorable relapse outcomes than all oral DMT comparators.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a kladribin $x terapeutické užití $7 D017338
- 650 _2
- $a fingolimod hydrochlorid $x terapeutické užití $7 D000068876
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a dimethyl fumarát $x terapeutické užití $7 D000069462
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a tablety $x terapeutické užití $7 D013607
- 650 _2
- $a recidiva $7 D012008
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Ozakbas, Serkan $u Dokuz Eylul University, Izmir, Turkey
- 700 1_
- $a Alroughani, Raed $u Al-Amiri Hospital, Kuwait City, Kuwait $1 https://orcid.org/0000000154365804
- 700 1_
- $a Terzi, Murat $u Department of Neurology, 19 Mayis University, Samsun, Turkey
- 700 1_
- $a Hodgkinson, Suzanne $u Liverpool Hospital, Sydney, NSW, Australia
- 700 1_
- $a Laureys, Guy $u University Hospital Ghent, Ghent, Belgium
- 700 1_
- $a Kalincik, Tomas $u MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia/CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia $1 https://orcid.org/0000000337781376 $7 xx0121848
- 700 1_
- $a Van Der Walt, Anneke $u Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia $1 https://orcid.org/0000000242787003
- 700 1_
- $a Yamout, Bassem $u Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates/American University of Beirut Medical Center, Beirut, Lebanon
- 700 1_
- $a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia/Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia $1 https://orcid.org/000000023850447X
- 700 1_
- $a Soysal, Aysun $u Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey
- 700 1_
- $a Kuhle, Jens $u Multiple Sclerosis Centre, Neurology, Departments of Head, Spine and Neuromedicine, Biomedicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland/Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland
- 700 1_
- $a Sanchez-Menoyo, Jose Luis $u Department of Neurology, Galdakao-Usansolo University Hospital, Osakidetza-Basque Health Service, Biocruces-Bizkaia Health Research Institute, Galdakao, Spain
- 700 1_
- $a Blanco Morgado, Yolanda $u Center of Neuroimmunology, Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain
- 700 1_
- $a Spitaleri, Daniele LA $u Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Ital
- 700 1_
- $a van Pesch, Vincent $u Cliniques Universitaires Saint-Luc (UCLouvain), Brussels, Belgium
- 700 1_
- $a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000319150036
- 700 1_
- $a Ampapa, Radek $u Nemocnice Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy $1 https://orcid.org/0000000269230846
- 700 1_
- $a Macdonell, Richard $u Department of Neurology, Austin Health, Melbourne, VIC, Australia
- 700 1_
- $a Al-Asmi, Abdullah $u Neurology Unit, Department of Medicine, College of Medicine & Health Sciences and Sultan Qaboos University Hospital, Sultan Qaboos University (SQU), Al Khodh, Oman
- 700 1_
- $a Gerlach, Oliver $u Academic MS Center Zuyderland, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands/School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
- 700 1_
- $a Oh, Jiwon $u Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada $1 https://orcid.org/0000000155196088
- 700 1_
- $a Altintas, Ayse $u Koc University School of Medicine and Koc University Research Center for Translational Medicine (KUTTAM), Istanbul, Turkey
- 700 1_
- $a Tundia, Namita $u EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
- 700 1_
- $a Wong, Schiffon L $u EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA
- 700 1_
- $a Butzkueven, Helmut $u MSBase Foundation, Melbourne, VIC, Australia/Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
- 773 0_
- $w MED00006389 $t Multiple sclerosis (Houndmills, Basingstoke, England) $x 1477-0970 $g Roč. 29, č. 2 (2023), s. 221-235
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36433775 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141330 $b ABA008
- 999 __
- $a ok $b bmc $g 1924830 $s 1190590
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 29 $c 2 $d 221-235 $e 20221126 $i 1477-0970 $m Multiple sclerosis $n Mult Scler $x MED00006389
- LZP __
- $a Pubmed-20230418
